| Objective To evaluate the clinical efficacy of irbesartan combined with pancreatic kininogenase in the treatment of early diabetic nephropathy. Methods From Jun 2013 to Mar 2015, eighty patients with early diabetic nephropathy were selected from our department and randomly divided into the control group and the treatment group, 40 cases in each group. Patients in the control group were treated with irbesartan alone, while the treatment group was given irbesartan and pancreatic kininogenase, and results of such indexes as 24-hour urinary albumin excretion rate (UAER), blood lipids, mean arterial pressure (MAP), hemodynamic changes between them were compared and analyzed. Results Fall in the levels of 24-hour UAER, blood lipids, MAP, and hemodynamic index were more notable in the treatment group than those in the control group, and the differences between them were significant (P<0.05). Conclusion Irbesartan combined with pancreatic kininogenase in the treatment of early diabetic nephropathy could improve the renal function effectively, delay the development of diabetic kidney disease, and therefore, it is worthy of clinical application. |
